Natera said it is preparing to accelerate prospective readouts to better establish the clinical utility of its Signatera MRD platform. On an earnings call alongside rising Q2 revenue, the company highlighted SIGNAL-ER 101, a sponsored interventional study designed to test whether MRD detection can guide escalation from endocrine therapy to CDK4/6 inhibitors after surgery in HR-positive, HER2-negative breast cancer. Natera positioned the SIGNAL portfolio as a broader set of interventional trials across multiple tumor types, and cited strong customer response reflected in booked orders. The company also reported Q2 revenue growth driven by increased test volumes and higher average selling prices, while noting instrument revenue declines tied to customer moderation ahead of Atera-linked shifts in spatial workflows.